

Dupilumab Treatment Improves Health-Related Quality of Life in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis

Amy S. Paller^{1,2}, Eric L. Simpson³, Elaine C. Siegfried^{4,5}, Michael J. Cork⁶, Andreas Wollenberg⁷, Peter D. Arkwright⁸, Haixin Zhang⁹, Zhixiao Wang⁹, Ainara Rodríguez Marco¹⁰

¹Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ²Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA;

³Oregon Health and Science University, Portland, OR, USA; ⁴Saint Louis University, St. Louis, MO, USA; ⁵Cardinal Glennon Children's Hospital, St. Louis, MO, USA;

⁶Sheffield Dermatology Research, University of Sheffield, Sheffield, UK; ⁷Ludwig-Maximilian University, Munich, Germany;

⁸Lydia Becker Institute of Immunology & Inflammation, University of Manchester, Manchester, UK; ⁹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ¹⁰Sanofi, Madrid, Spain

Contact author

Amy S. Paller, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Email: apaller@northwestern.edu

Disclosures

Paller AS: AbbVie, AnaptysBio, Eli Lilly, Incyte, Janssen, Krystal Biotech, Regeneron Pharmaceuticals, Inc., UCB – investigator; AbbVie, Abeona Therapeutics, Alcedim, Almirall, Amagma, AnaptysBio, Arena Pharmaceuticals, Azitra, BiomX, Boehringer Ingelheim, Castle Creek Biosciences, Catawba Research, Dermira, Eli Lilly, Excure, Forté, Kamari Pharma, LEO Pharma, LifeMax, NAOs, Novartis, Pfizer, Phoenix, Pierre Fabre Dermo-Cosmetics, Regeneron Pharmaceuticals, Inc., Sanofi, Seanergy, Trifecta Pharmaceuticals, UCB – consultant with honorarium; AbbVie, Bausch Health, Galderma, Novan – data and safety monitoring board. **Simpson EL:** AbbVie, Boehringer Ingelheim, Collective Acumen, Eli Lilly, Forté, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Pierre Fabre Dermo-Cosmetics, Regeneron Pharmaceuticals, Inc., Roivant Sciences, Sanofi, Valeant – personal fees; AbbVie, Eli Lilly, Incyte, Kyowa Hakko Kirin, LEO Pharma, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Tioga Pharmaceuticals, Vanda Pharmaceuticals – grants/Principal Investigator. **Cork MJ:** AbbVie, Astellas Pharma, Boots, Dermavant, Galapagos, Galderma, Hyphens Pharma, Johnson & Johnson, LEO Pharma, L'Oréal, Menlo Therapeutics, Novartis, Oxagen, Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals, Inc., Sanofi – investigator and/or consultant. **Wollenberg A:** Beiersdorf, Eli Lilly, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi – investigator; AbbVie, Almirall, Anacor Pharmaceuticals, Eli Lilly, Galapagos, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi – consultant; Beiersdorf, LEO Pharma, Pierre Fabre – research grants. **Arkwright PD:** Regeneron Pharmaceuticals, Inc. – investigator; Sanofi Genzyme – research grant, advisor. **Zhang H, Wang Z:** Regeneron Pharmaceuticals, Inc. – employees and shareholders. **Rodríguez Marco A:** Sanofi – employee, may hold stock and/or stock options in the company.

Acknowledgments


Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT03346434. Medical writing/editorial assistance was provided by Holly Rocliffe, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the [Good Publication Practice guideline](#).

Methods

Objective: To determine the impact of 16-week dupilumab treatment with concomitant low-potency TCS on HRQoL in children aged 6 months to 5 years with moderate-to-severe AD inadequately controlled with topical therapies and their caregivers

Analysis: Children aged 6 months to 5 years with moderate-to-severe AD inadequately controlled with topical therapies were randomized 1:1 to SC dupilumab q4w (200 mg if baseline weight ≥ 5 to < 15 kg, 300 mg if ≥ 15 to < 30 kg) or placebo for 16 weeks with concomitant low-potency TCS





LIBERTY AD INFANT/PRE-SCHOOL study design



^aStarting on Day -14, all patients were to initiate a standardized low-potency TCS treatment regimen (hydrocortisone acetate 1% cream). ^bNumber of patients with IGA score of 3 was capped to 40.

^cNo loading dose. Weight-tiered doses were assigned by baseline body weight for the duration of the study. AD, atopic dermatitis; BSA, body surface area; EASI, Eczema Area and Severity Index; HRQoL, health-related quality of life; IGA, Investigator's Global Assessment; q4w, every 4 weeks; R, randomization; SC, subcutaneous; TCS, topical corticosteroids.

Rapid and significant improvement in IDQoL, CDLQI, and DFI scores in children aged 6 months to 5 years treated with dupilumab for 16 weeks and their caregivers



Photos of a 5-year-old, white female patient at baseline and after receiving 200 mg dupilumab q4w for 16 weeks, representing an LS mean change of -10.0 in CDLQI from baseline in the dupilumab treated population.

*P < 0.05; ****P < 0.0001; *****P < 0.00001 vs placebo; CDLQI, Children's Dermatology Life Quality Index; DFI, Dermatitis Family Impact; IDQoL, Infants' Dermatology Quality of Life Index; LS, least squares; QoL, quality of life; SE, standard error.

Safety and discussion

- Dupilumab has demonstrated an acceptable safety profile¹

Discussion

- Dupilumab treatment for 16 weeks with low-potency TCS rapidly and significantly improved HRQoL measures as early as Week 2, with improvements continuing to Week 16
- This significant improvement to HRQoL measures was reflected in the CDLQI, IDQoL, and DFI scores in children aged 6 months to 5 years with moderate-to-severe AD and their caregivers